首頁 > 市場調查報告書 > 醫療設備

心血管設備

市場調查報告書

商品編碼

2112456

無導線心律調節器：市場洞察、競爭格局和市場預測 - 2034 年

Leadless Pacemakers - Market Insights, Competitive Landscape, and Market Forecast - 2034

出版日期: 2026年08月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

概述：

2025 年，無導線心律調節器市場規模估計為 4.277 億美元，預計到 2034 年將達到 10.1 億美元。這一成長是由全球緩慢性心律不整負擔加重、臨床轉向微創無導線心臟節律管理以及心搏過緩心律調節器和心臟再同步治療 (CRT)商業性適應症的擴大所推動的。
全球無導線心律調節器市場預計在 2026 年至 2034 年的預測期內將以 9.6% 的複合年成長率成長。
按產品類型分類，預計到 2025 年，單腔無導線心律調節器細分市場將佔 68% 的市場佔有率，從而推動無導線心律調節器市場的發展。
按技術分類，預計到 2025 年，主動固定技術細分市場將佔 58% 的市場佔有率，從而推動無引線空間製造器市場的發展。
從適應症來看，預計到 2025 年，心搏過緩領域將佔無導線心律調節器市場 52.3% 的市佔率。
按最終用戶分類，預計到 2025 年，醫院領域將佔市場佔有率的 55.9%，從而推動無導線心律調節器市場的發展。
預計到 2025 年，北美將佔 42% 的市場佔有率，推動全球無導線心律調節器市場的銷售，並成為全球市場佔有率最高的地區。

無導線心律調節器是一種小型、自主型的心臟節律管理裝置，透過微創經靜脈導管途徑直接植入心腔，無需傳統心律調節器所需的經靜脈導線和皮下脈衝發生器囊袋。這些裝置的尺寸約為傳統心律調節器的十分之一，將電池、電子線路和起搏電極整合在一個膠囊內，並固定在心內膜上，從而降低了與導線和囊袋相關的併發症風險，例如斷裂、移位、感染和靜脈阻塞。市場按產品類型（單腔和雙腔系統）、技術（包括被動固定、主動固定、裝置間無線通訊和其他新興技術）、適應症（主要用於心搏過緩、房室傳導阻滯和心房顫動）以及最終用戶（醫院、專科心臟醫療中心和門診手術中心）進行細分。隨著雙腔植入式設備間（i2i）通訊技術的商業化應用、用於心臟再同步治療（CRT）的無導線左心室起搏的出現，以及老齡化社會中心率心律失常發病率的增加，無導線心律調節器正成為全球心臟節律管理領域日益主流的選擇。

無導線心律調節器市場的主要成長要素

雙腔無導線心律調節器的商業性擴張正在推動需求，雅培的 Aveir DR 系統於 2023 年 7 月獲得 FDA 批准，使大約 80% 需要在心臟兩個心室進行起搏的心律調節器患者能夠接受無導線治療。
全球心血管疾病和心搏過緩負擔日益加重，推動了心臟節律治療需求的成長。根據世界衛生組織（世衛組織）統計，每年約有1,790萬人死於心血管疾病。
醫院和電生理中心擴大採用無導線系統作為經靜脈心律調節器的替代方案，以降低導線和囊袋相關感染疾病、脫落和再次干預的風險，縮短恢復時間，並減輕手術負擔。
隨著美敦力「Micra AV2」和「VR2」（2023 年 5 月獲得 FDA 批准，2024 年 1 月獲得 CE 認證）等新一代產品的核准和應用範圍擴大，這些產品具有更長的電池壽命和自動 AV 同步演算法，其在臨床環境中的應用正在不斷擴大。
EBR Systems 的 WiSE CRT 系統於 2025 年 4 月獲得 FDA 批准，是第一個用於心臟再同步治療 (CRT) 的無導線左心室心律調節器，將無導線技術擴展到心臟衰竭和 CRT 領域。
有利的報銷趨勢，例如 CMS 對 Aveir VR、AR 和 DR 的「循證覆蓋」研究，以及 Medicare 支持 WiSE CRT 的決定，正在降低最大市場採用這些技術的門檻。
醫生培訓的加強、電生理基礎設施的擴展，以及印度等新興市場植入手術的增加（雅培和薩克特馬克斯醫院於 2025 年 10 月在印度進行了該國首例雙腔 Aveir 植入手術），正在擴大該技術的地理覆蓋範圍。
雙腔產品的商業化、CRT 的擴張、人口老化以及有利的還款環境，所有這些因素共同推動市場保持中等個位數到中等兩位數的較高成長率，直至 2034 年。

推動無導線心律調節器市場成長的因素

市場促進因素

雙腔無導線心律調節器的商業性擴張

無導線心律調節器市場最強勁的驅動力是雙腔無導線心律調節器的商業性化。雅培的Aveir DR系統於2023年7月獲得FDA批准，是全球首個雙腔無導線心律調節器系統，它透過設備間（i2i）通訊技術將先前獲準的心室節律器Aveir VR與新核准的心房心律調節器Aveir AR連接起來。由於約80%需要心律調節器的患者需要同時治療雙心搏過緩，雙腔系統的核准將顯著擴大目標患者群體，使其不再局限於先前傳統無導線系統主要針對的單心室心搏過緩患者。雅培報告稱，Aveir產品線的加速推廣已推動其心臟節律管理業務在2025年之前實現兩位數的銷售成長，預計在預測期內，隨著臨床和地域範圍的進一步擴大，市場需求將保持強勁，其中包括2025年10月在印度推出首款雙腔Aveir植入裝置。

全球心血管疾病和心搏過緩的負擔日益加重。

全球心血管疾病負擔日益加重，推動了對心律調節器治療及其相關醫療設備的需求。根據世界衛生組織（WHO）統計，每年約有1790萬人死於心血管疾病。北美、歐洲和亞太地區人口老化加劇，導致心搏過緩、房室傳導阻滯和其他傳導障礙的發生率上升，這些疾病均需要永久性心搏器治療。無導線心律調節器因其避免了傳統心律調節器系統中導線和囊袋帶來的併發症，正日益受到關注，成為此類患者的一線治療選擇。隨著心律不整和傳導障礙的盛行率隨人口老化而增加，預計到2034年，心律調節器植入手術的數量以及相關的CDMO（合約研發生產組織）型製造和臨床基礎設施將穩步成長。

市場限制因素

儘管無導線心律調節器市場發展勢頭強勁，但仍面臨諸多限制因素。與傳統經靜脈心律調節器相比，無導線心律調節器較高的初始成本仍然是一個主要障礙，尤其是在對價格敏感且報銷額度較低的醫療體系中，這可能會限制其在資源充足的醫院和專科醫療中心以外的普及。手術的複雜性以及對專業電生理訓練的需求限制了能夠進行植入手術的醫生數量。此外，美國食品藥物管理局 (FDA) 2021 年的一份安全報告強調了早期無導線心律調節器可能導致心臟壁穿孔的風險，這促使一些臨床機構對其應用仍持謹慎態度。關於器械移除、多個器械的長期管理以及對血管和心內膜的慢性負擔（尤其是在患者一生中植入多個無導線植入裝置的情況下）等問題仍未解決。在美國和少數已開發市場以外，新型雙腔和 CRT 相容型無導線系統的報銷政策仍然不均衡，而且市場仍然集中在少數幾家獲得批准的製造商手中。這限制了價格競爭，並可能減緩成本受限的醫療保健系統中微創手術的普及速度。成本、訓練、安全監測和保險報銷等方面的障礙，加上推動微創手術普及的根本因素（例如人口老化和適應症擴大），共同減緩了微創手術的成長速度，儘管這些因素依然存在。

無導線暫停製造商市場：市場促進因素
- 雙腔無引線空間製造器的商業性開發
- 全球心血管疾病負擔日益加重
- 過渡到微創、無導線心律不整管理
- 進入心臟再同步治療領域
無導線心律調節器市場：限制因素與挑戰
- 高成本且保險賠償金額波動較大。
- 流程複雜性和培訓要求
- 安全監測和醫療設備召回注意事項
無導線暫停製造商市場：市場機會
- 無導線心臟再同步治療的擴展
- 進入新興市場和醫生培訓

第4章：人工智慧、地緣政治、貿易與經濟趨勢

第5章：監理分析

美國
歐洲
日本
中國

第6章：波特五力分析

第7章：無導線心律調節器市場：評估

依產品類型
- 單腔無引線空間製造器
- 雙腔無引線空間製造器
透過技術
- 被動固定技術
- 主動固定技術
- 無線設備間通訊
- 其他
適應症
- 心搏過緩
- 房室傳導阻滯
- 心房顫動
- 其他
最終用戶
- 醫院
- 心臟病診所
- 門診手術中心
按地區
- 北美洲
- 歐洲
- 亞太地區
- 世界其他地區

第8章：無導線心律調節器市場：競爭格局

市場集中度與結構
競爭定位與市場佔有率分析（加值服務）

第9章：無鉛Pasmo市場：新創企業資金籌措與投資趨勢

第10章：無導線暫停設備製造商市場：公司概況與產品概況

Abbott
Medtronic
BIOTRONIK
Boston Scientific Corporation
MicroPort Scientific Corporation
Lepu Medical
OSYPKA
Shree Pacetronix
EBR Systems

第10章奧斯科爾

公司簡介
公司簡介
財務概覽
產品線
戰略方法/熵

第11章：KOL的觀點

第12章：專案式教學方法

第13章：關於 DelveInsight

第14章免責聲明與聯絡方式

簡介目錄圖表

Product Code: DIMDCL0972

Leadless Pacemakers Market Summary

Overview:

The Leadless Pacemakers market is estimated at USD 427.7 million in 2025 and is projected to reach USD 1,000.1 million by 2034. Growth is anchored in the rising global burden of bradyarrhythmia, the clinical shift toward minimally invasive, lead-free cardiac rhythm management, and the commercial expansion of dual-chamber and cardiac resynchronization therapy (CRT) indications.
The global Leadless Pacemakers market is growing at a CAGR of 9.6% during the forecast period from 2026 to 2034.
By product type, the single-chamber leadless pacemakers segment dominated the Leadless Pacemakers market with a 68% share in 2025.
By technology, the active fixation technology segment dominated the Leadless Pacemakers market with a 58% share in 2025.
By indication, the bradycardia segment dominated the Leadless Pacemakers market with a 52.3% share in 2025.
By end-user, the hospitals segment dominated the Leadless Pacemakers market with a 55.9% share in 2025.
North America dominated the global Leadless Pacemakers market revenue with a 42% share in 2025, representing the highest regional market share globally.

A leadless pacemaker is a miniaturized, self-contained cardiac rhythm management device that is implanted directly inside a heart chamber via a minimally invasive, catheter-based transvenous approach, eliminating the transvenous leads and subcutaneous pulse-generator pocket required by conventional pacemakers. Roughly one-tenth the size of a traditional pacemaker, these devices combine the battery, electronics, and pacing electrode within a single capsule that is fixed to the endocardium, reducing exposure to lead-related and pocket-related complications such as fracture, dislodgement, infection, and venous obstruction. The market is organized by product type across single-chamber and dual-chamber systems; by technology, including passive fixation, active fixation, wireless device-to-device communication, and other emerging approaches; by indication, led by bradycardia, atrioventricular (AV) block, and atrial fibrillation; and by end-user, spanning hospitals, cardiac specialty centers, and ambulatory surgical centers. Driven by the commercial rollout of dual-chamber implant-to-implant (i2i) communication technology, the entry of leadless left ventricular endocardial pacing for CRT, and an aging population with rising bradyarrhythmia incidence, leadless pacemakers have become an increasingly mainstream alternative within the global cardiac rhythm management landscape.

Leadless Pacemakers Market Key Growth Drivers

The commercial expansion of dual-chamber leadless pacing is driving demand, with Abbott's Aveir DR system, approved by the FDA in July 2023, unlocking leadless therapy for the roughly 80% of pacemaker patients who require pacing in two heart chambers.
The rising global burden of cardiovascular disease and bradyarrhythmia is expanding demand for pacing therapy, with the World Health Organization attributing nearly 17.9 million deaths annually to cardiovascular disease.
Hospitals and electrophysiology centers are increasingly adopting leadless systems over transvenous pacemakers to reduce lead- and pocket-related infection, dislodgement, and reintervention risk, shortening recovery time and procedural burden.
Next-generation product approvals and label expansions, including Medtronic's Micra AV2 and VR2 (FDA approval May 2023; CE Mark January 2024) offering longer battery life and automated AV-synchrony algorithms, are broadening clinical adoption.
The April 2025 FDA approval of EBR Systems' WiSE CRT System, the first leadless left ventricular endocardial pacing device for cardiac resynchronization therapy, is extending leadless technology into the heart-failure and CRT segment.
Favorable reimbursement momentum, including CMS Coverage with Evidence Development studies for Aveir VR, AR, and DR and a Medicare coverage decision supporting WiSE CRT, is easing adoption barriers in the largest market.
Growing physician training, expanding electrophysiology infrastructure, and rising implant volumes in emerging markets such as India, where Abbott and Max Hospital, Saket launched the country's first dual-chamber Aveir implant in October 2025, are widening geographic reach.
The convergence of dual-chamber commercialization, CRT expansion, an aging population, and favorable reimbursement is expected to sustain high-single-digit to low-double-digit growth in the market through 2034.

Key Companies in Leadless Pacemakers Market

The competitive landscape is led by the following active manufacturers:

Abbott
Medtronic
BIOTRONIK
Boston Scientific
MicroPort Scientific Corporation
Lepu Medical
OSYPKA
Shree Pacetronix
EBR Systems
Oscor

Factors Contributing to the Growth of the Leadless Pacemakers Market

Market Drivers

Commercial Expansion of Dual-Chamber Leadless Pacing

The most powerful driver of the Leadless Pacemakers market is the commercial rise of dual-chamber leadless pacing. Abbott's Aveir DR system, approved by the FDA in July 2023, was the world's first dual-chamber leadless pacing system, pairing the previously approved Aveir VR ventricular device with the newly authorized Aveir AR atrial device through implant-to-implant (i2i) communication technology. Because roughly 80% of patients who require pacing need therapy in two chambers of the heart, dual-chamber approval materially widens the addressable population beyond the single-chamber bradycardia patients historically served by leadless systems. Abbott reported that accelerating adoption of its Aveir portfolio drove double-digit sales growth in its Cardiac Rhythm Management business through 2025, and further clinical and geographic rollout, including the October 2025 launch of India's first dual-chamber Aveir implant, is expected to sustain demand through the forecast period.

Rising Global Cardiovascular Disease and Bradyarrhythmia Burden

The growing global burden of cardiovascular disease is expanding demand for pacing therapy and the devices that deliver it. The World Health Organization attributes nearly 17.9 million deaths annually to cardiovascular disease, and aging populations across North America, Europe, and Asia-Pacific are experiencing rising incidence of bradycardia, atrioventricular block, and other conduction disorders that require permanent pacing. Leadless pacemakers are increasingly considered a first-line option for these patients because they eliminate the lead- and pocket-related complications associated with conventional systems. As the prevalence of arrhythmia and conduction disease rises alongside an aging population, the volume of implant procedures and the CDMO-like manufacturing and clinical infrastructure that supports them is expected to grow steadily through 2034.

Market Restraints

Despite strong momentum, the Leadless Pacemakers market faces material constraints. The high upfront cost of leadless devices relative to conventional transvenous pacemakers remains a significant barrier, particularly in price-sensitive and lower-reimbursement healthcare systems, and can limit adoption outside well-resourced hospitals and specialty centers. Procedural complexity and the need for specialized electrophysiology training constrain the pool of physicians able to perform implants, and the 2021 FDA safety communication highlighting a potential risk of cardiac perforation associated with early leadless pacemaker generations continues to inform cautious adoption in some clinical settings. Device retrieval and long-term multi-device management, particularly as patients accumulate more than one leadless implant over a lifetime, raise unresolved questions around chronic vessel and endocardial burden. Reimbursement policy for newer dual-chamber and CRT-indicated leadless systems remains uneven outside the United States and a small number of developed markets, and the market remains concentrated among a limited number of approved manufacturers, which can constrain price competition and slow adoption in cost-constrained health systems. Together, these cost, training, safety-surveillance, and reimbursement barriers temper the pace of growth even as the underlying drivers of minimally invasive adoption, an aging population, and expanding indications remain firmly intact.

Leadless Pacemakers Market Segment Analysis

The leadless pacemakers market by product type (single-chamber leadless pacemakers and dual-chamber leadless pacemakers), technology (passive fixation technology, active fixation technology, wireless device-to-device communication, and others), indication (bradycardia, atrioventricular (av) block, atrial fibrillation, and other), end-users (hospitals, cardiac specialty centers, ambulatory surgical centers, and others), and geography (North America, Europe, Asia-Pacific, and Rest of World).

By Product Type

Dominant Subsegment: Single-Chamber Leadless Pacemakers.

The single-chamber leadless pacemakers segment accounted for 68% of the Leadless Pacemakers market in 2025. Single-chamber devices, such as Medtronic's Micra VR/VR2 and Abbott's Aveir VR, are the leading product type because they address the largest historically approved patient population, those requiring ventricular-only pacing for bradycardia with normal sinus rhythm, and because they carry the longest clinical track record, the broadest base of trained implanters, and the most established reimbursement pathways. Their smaller regulatory and procedural footprint has allowed single-chamber systems to achieve the widest hospital and specialty-center penetration to date. While dual-chamber leadless pacemakers are the fastest-growing product type, propelled by Abbott's Aveir DR i2i platform unlocking therapy for patients needing atrioventricular synchrony, the depth of clinical experience, established indications, and procedural simplicity of single-chamber systems secure the segment's leadership across the forecast period.

By Technology

Dominant Subsegment: Active Fixation Technology.

The active fixation technology segment accounted for 58% of the Leadless Pacemakers market in 2025. Active fixation, in which a helix or screw-in mechanism secures the device directly to the endocardium, is the leading technology because it provides more reliable long-term lead-free attachment, lower dislodgement risk, and, in systems such as Abbott's Aveir platform, enables device retrievability for replacement or repositioning. Nearly all commercially approved leadless pacemakers, including Medtronic's Micra family and Abbott's Aveir VR, AR, and DR systems, rely on active fixation, reinforcing its dominant position. Wireless device-to-device communication, the enabling technology behind dual-chamber i2i synchronization and future multi-device coordination, is the fastest-growing technology category as dual-chamber and CRT-oriented systems scale, while passive fixation and other emerging approaches, including EBR Systems' ultrasound-based leadless left ventricular endocardial pacing, represent smaller but strategically important niches. Nonetheless, the proven reliability and retrievability advantages of active fixation secure its leadership across the forecast period.

Leadless Pacemakers Market Region Analysis

Dominant Region: North America

North America accounted for 42% of the global Leadless Pacemakers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the concentration of pioneering FDA approvals, including Medtronic's original 2016 Micra approval and Abbott's Aveir VR, AR, and DR approvals, alongside a dense network of high-volume electrophysiology centers, favorable CMS reimbursement pathways, and rapid physician adoption of dual-chamber and CRT-indicated leadless technology. The United States hosts the largest concentration of leadless implant volume and the broadest base of trained implanting physicians, and Abbott has reported accelerating Aveir adoption driving double-digit growth in its cardiac rhythm management business. Ongoing CMS Coverage with Evidence Development studies and the 2025 approval and Medicare evaluation of EBR Systems' WiSE CRT System further reinforce the region's regulatory and reimbursement leadership, anchoring North America's continued dominance across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Leadless Pacemakers market. The region's elevated CAGR is driven by rising cardiovascular disease prevalence, expanding electrophysiology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's domestic manufacturers, including MicroPort Scientific Corporation and Lepu Medical, are localizing cardiac rhythm management portfolios and building implant capability; Japan is expanding electrophysiology training, and India is scaling access following Abbott's November 2024 Aveir VR launch and the October 2025 launch of the country's first dual-chamber Aveir implant at Max Hospital, Saket. Government healthcare investment, an expanding base of trained implanting physicians, and rising awareness of minimally invasive pacing options are accelerating adoption, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 42% of the global Leadless Pacemakers market revenue in 2025. The United States dominates on the strength of its pioneering FDA approval history, dense electrophysiology infrastructure, favorable CMS reimbursement pathways, and the accelerating commercial rollout of Abbott's Aveir DR dual-chamber and EBR Systems' WiSE CRT platforms, while ongoing Coverage with Evidence Development studies reinforce continued adoption.

Europe

Europe is a large and advanced regional market, supported by established CE Mark regulatory pathways, a strong base of academic electrophysiology centers, and growing adoption of next-generation devices such as Medtronic's Micra AV2 and VR2, which received CE Mark approval in January 2024. Manufacturers including BIOTRONIK and OSYPKA maintain a strong regional manufacturing and clinical presence across Germany, France, the United Kingdom, Italy, and Spain, supporting continued adoption of leadless pacing technology.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease incidence, expanding electrophysiology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Localization efforts by MicroPort Scientific Corporation and Lepu Medical in China, alongside Abbott's expanding Aveir footprint in India, are accelerating regional adoption and clinical-training activity.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac-care infrastructure, rising diagnosis rates for bradyarrhythmia and conduction disorders, and gradual introduction of leadless pacing technology by global manufacturers are broadening access, while training partnerships and distributor relationships support the build-out of regional implant capability.

Leadless Pacemakers Market Competitive Landscape

The Leadless Pacemakers market is classified as Highly Concentrated. Abbott and Medtronic together anchor the top tier through deep patent estates, long-running registry datasets, and captive delivery-tool ecosystems, with Abbott leveraging i2i communication for dual-chamber pacing and Medtronic sustaining broad payer coverage through its accelerometer-based AV-synchrony algorithm. Boston Scientific is advancing its Empower Modular Pacing System, aiming to integrate subcutaneous ICD therapy with leadless pacing, while EBR Systems has established a differentiated position in leadless CRT following its 2025 WiSE System approval. Established cardiac rhythm management manufacturers, including BIOTRONIK, MicroPort Scientific Corporation, Lepu Medical, OSYPKA, Shree Pacetronix, and Oscor, compete through regional manufacturing strength, distribution reach, and adjacent device portfolios, increasing competitive intensity as leadless technology adoption broadens.

The competitive landscape can be evaluated across the following dimensions:

Market concentration: Highly concentrated, with Abbott and Medtronic anchoring the market and a growing field of specialized and regional challengers.
Leading players: Abbott and Medtronic lead through deep patent estates, long-running registry data, and captive delivery-tool ecosystems.
Geographic reach: Leaders operate global commercial networks with deep penetration in North America and Europe and expanding footprints in Asia-Pacific.
Product portfolio strength: Top players offer single-chamber, dual-chamber, and, increasingly, CRT-oriented leadless platforms with wireless device-to-device communication.
Clinical evidence base: Long-term registry and Coverage with Evidence Development data, including Micra CED and Aveir VR, AR, and DR studies, is a decisive competitive advantage.
Strategic partnerships: Collaborations such as Orchestra BioMed's 2025 financing from Medtronic and Ligand Pharmaceuticals to advance late-stage cardiology programs extend innovation reach.
Regional manufacturing: Companies including MicroPort Scientific Corporation and Lepu Medical are localizing cardiac rhythm management manufacturing in China to build domestic volume advantage.
Manufacturing capabilities: Miniaturized capsule engineering, active-fixation delivery systems, and wireless synchronization electronics are key competitive moats.
Innovation focus: Dual-chamber synchronization, leadless CRT, extended battery life, device retrievability, and multi-device compatibility.

Leadless Pacemakers Market Recent Developmental Activities

In October 2025, Abbott and Max Hospital, Saket, announced the launch of India's first dual-chamber leadless Aveir pacemaker implant, expanding access to next-generation cardiac rhythm management technology.

In 2025, Abbott reported that accelerating adoption of its AVEIR leadless pacemaker portfolio drove double-digit growth in its Cardiac Rhythm Management business, following the 2023 approval of the dual-chamber AVEIR DR system.

Leadless Pacemakers Market Segmentation

Leadless Pacemakers Market by Product Type

Single-Chamber Leadless Pacemakers
Dual-Chamber Leadless Pacemakers

Leadless Pacemakers Market by Technology

Passive Fixation Technology
Active Fixation Technology
Wireless Device-to-Device Communication
Others

Leadless Pacemakers Market by Indication

Bradycardia
Atrioventricular (AV) Block
Atrial Fibrillation
Other

Leadless Pacemakers Market by End-User

Hospitals
Cardiac Specialty Centers
Ambulatory Surgical Centers
Others

Leadless Pacemakers Market by Geography

North America Leadless Pacemakers Market
United States Leadless Pacemakers Market Size in USD million (2023-2034)
Canada Leadless Pacemakers Market Size in USD million (2023-2034)
Mexico Leadless Pacemakers Market Size in USD million (2023-2034)
Europe Leadless Pacemakers Market
Germany Leadless Pacemakers Market Size in USD million (2023-2034)
United Kingdom Leadless Pacemakers Market Size in USD million (2023-2034)
France Leadless Pacemakers Market Size in USD million (2023-2034)
Italy Leadless Pacemakers Market Size in USD million (2023-2034)
Spain Leadless Pacemakers Market Size in USD million (2023-2034)
Rest of Europe Leadless Pacemakers Market Size in USD million (2023-2034)
Asia-Pacific Leadless Pacemakers Market
China Leadless Pacemakers Market Size in USD million (2023-2034)
Japan Leadless Pacemakers Market Size in USD million (2023-2034)
India Leadless Pacemakers Market Size in USD million (2023-2034)
Australia Leadless Pacemakers Market Size in USD million (2023-2034)
South Korea Leadless Pacemakers Market Size in USD million (2023-2034)
Rest of Asia-Pacific Leadless Pacemakers Market Size in USD million (2023-2034)
Rest of the World (RoW) Leadless Pacemakers Market
Middle East Leadless Pacemakers Market Size in USD million (2023-2034)
Africa Leadless Pacemakers Market Size in USD million (2023-2034)
South America Leadless Pacemakers Market Size in USD million (2023-2034)

Key Takeaways from the Leadless Pacemakers Market Report Study

Market size analysis for the current leadless pacemakers market size (2025), and market forecast for 9 years (2026 to 2034).
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
Key companies dominating the global leadless pacemakers market.
Various opportunities available for competitors in the leadless pacemakers market space.
What are the top-performing segments in 2025? How will these segments perform in 2034?
Which are the top-performing regions and countries in the current leadless pacemakers market scenario?
Which are the regions and countries where companies should concentrate their opportunities for leadless pacemakers market growth in the future?

Target audience who can benefit from this leadless pacemakers market report study

Leadless pacemakers product providers
Research organizations and consulting companies
Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in leadless pacemakers
Various end-users who want to know more about the leadless pacemakers market and the latest technological developments in the leadless pacemakers market.

Frequently Asked Questions:

Q1. What is the growth rate of the leadless pacemakers market?

The leadless pacemakers market is projected to expand at a CAGR of 9.6% during the forecast period from 2026-2034.

Q2. What is the market size of the leadless pacemakers market?

The leadless pacemakers market is estimated at USD 427.7 million in 2025 and is projected to reach USD 1,000.1 million by 2034.

Q3. Which region dominates the leadless pacemakers market?

North America dominated the Leadless Pacemakers market with a 42% share of global revenue in 2025, supported by pioneering FDA approvals, dense electrophysiology infrastructure, favorable CMS reimbursement pathways, and the largest concentration of trained implanting physicians. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the leadless pacemakers market?

The principal drivers are the commercial expansion of dual-chamber leadless pacing following Abbott's 2023 AVEIR DR approval; the rising global cardiovascular disease and bradyarrhythmia burden, with the World Health Organization attributing nearly 17.9 million deaths annually to cardiovascular disease; the clinical shift toward minimally invasive, lead-free rhythm management; next-generation product approvals such as Medtronic's Micra AV2 and VR2; and the 2025 entry of leadless technology into cardiac resynchronization therapy through EBR Systems' WiSE CRT System.

Q5. Who are the major players in the leadless pacemakers market?

The major players include Abbott, Medtronic, BIOTRONIK, Boston Scientific, MicroPort Scientific Corporation, Lepu Medical, OSYPKA, Shree Pacetronix, EBR Systems, and Oscor, among other active manufacturers profiled in the Competitive Landscape section. Abbott and Medtronic lead the market through dual-chamber and next-generation single-chamber platform depth.

1. Leadless Pacemakers Market Report Introduction

1.1 Scope of the Study
1.2 Market Segmentation
1.3 Market Assumptions

2. Leadless Pacemakers Market Executive Summary

2.1 Market at a Glance

3. Leadless Pacemakers Market Key Factors Analysis

3.1 Leadless Pacemakers Market Drivers
- 3.1.1 Commercial Expansion of Dual-Chamber Leadless Pacing
- 3.1.2 Rising Global Cardiovascular Disease Burden
- 3.1.3 Shift Toward Minimally Invasive, Lead-Free Rhythm Management
- 3.1.4 Entry into Cardiac Resynchronization Therapy
3.2 Leadless Pacemakers Market Restraints and Challenges
- 3.2.1 High Device Cost and Reimbursement Variability
- 3.2.2 Procedural Complexity and Training Requirements
- 3.2.3 Safety Surveillance and Device Retrieval Considerations
3.3 Leadless Pacemakers Market Opportunities
- 3.3.1 Leadless Cardiac Resynchronization Therapy Expansion
- 3.3.2 Emerging-Market Access and Physician Training

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

5.1 United States
5.2 Europe
5.3 Japan
5.4 China

6. Leadless Pacemakers Market Porter's Five Forces Analysis

6.1 Bargaining Power of Suppliers
6.2 Bargaining Power of Buyers
6.3 Threat of New Entrants
6.4 Threat of Substitutes
6.5 Competitive Rivalry

7. Leadless Pacemakers Market Assessment

7.1 By Product Type
- 7.1.1 Single-Chamber Leadless Pacemakers
- 7.1.2 Dual-Chamber Leadless Pacemakers
7.2 By Technology
- 7.2.1 Passive Fixation Technology
- 7.2.2 Active Fixation Technology
- 7.2.3 Wireless Device-to-Device Communication
- 7.2.4 Others
7.3 By Indication
- 7.3.1 Bradycardia
- 7.3.2 Atrioventricular (AV) Block
- 7.3.3 Atrial Fibrillation
- 7.3.4 Other
7.4 By End-Users
- 7.4.1 Hospitals
- 7.4.2 Cardiac Specialty Clinics
- 7.4.3 Ambulatory Surgical Centers
- 7.4.4 Others
7.5 By Geography
- 7.5.1 North America
  - 7.5.1.1 United States Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.1.2 Canada Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.1.3 Mexico Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.2 Europe
  - 7.5.2.1 Germany Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.2.2 United Kingdom Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.2.3 France Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.2.4 Italy Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.2.5 Spain Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.2.6 Rest of Europe Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.3 Asia-Pacific
  - 7.5.3.1 China Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.3.2 Japan Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.3.3 India Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.3.4 Australia Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.3.5 South Korea Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.3.6 Rest of Asia-Pacific Aspiration Devices Market Size in USD million (2023-2034)
- 7.5.4 Rest of World
  - 7.5.4.1 Middle East Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.4.2 Africa Aspiration Devices Market Size in USD million (2023-2034)
  - 7.5.4.3 South America Aspiration Devices Market Size in USD million (2023-2034)

8. Leadless Pacemakers Market Competitive Landscape

8.1 Market Concentration and Structure
8.2 Competitive Positioning and Market Share Analysis (Premium Offering)

9. Leadless Pacemakers Market Startup Funding and Investment Trends

10. Leadless Pacemakers Market Company and Product Profiles

10.1 Abbott
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
10.2 Medtronic
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
10.3 BIOTRONIK
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
10.4 Boston Scientific Corporation
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
10.5 MicroPort Scientific Corporation
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
10.6 Lepu Medical
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
10.7 OSYPKA
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
10.8 Shree Pacetronix
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
10.9 EBR Systems
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy

10. Oscor

10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Financial Overview
10.10.4 Product Portfolio
10.10.5 Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.